SOURCE: Phoenix Marketing International

December 12, 2011 09:27 ET

Phoenix's Oncology Advisory Board Shows FDA's Decision to Revoke Avastin for mBC Will Have Widespread and Immediate Impact on Treatment

RESEARCH TRIANGLE PARK, NC--(Marketwire - Dec 12, 2011) - Shortly after the FDA announced revoking Avastin's breast cancer indication, oncologists on Phoenix's Oncology Advisory Board were asked their expected behavior as a result of the decision. The 58 physicians indicated that they would remove many patients currently taking the treatment for mBC and would generally not start new mBC patients on Avastin.

The Avastin ruling will also impact chemotherapy choices, most notably first-line taxane use. Several Advisory Board members mention using abraxane more as a first-line agent. One Advisory Board member states, "I will use less taxol as [a] first-line agent; instead I will use abraxane/xeloda." This may also impact usage of supportive care if regimen toxicity is altered.

The Phoenix Oncology Advisory Board is a proprietary community of practicing oncologists who treat a variety of tumor types. It is a market research initiative designed to provide quick, continuous, and cost-effective access to valued oncologists. In December, the survey focuses on information coming out of the San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) conference, such as the positive clinical trial data on both Genentech's pertuzumab and Novartis AG's everolimus (Afinitor).

Access to the community is provided through a subscription that includes monthly reporting and summary findings tailored to each client. Additionally, subscribers submit their own monthly questions to address internal hot topics. The subscription also permits access to the Advisory Board to conduct ad hoc research such as in-depth interviews.

Additional findings from the November survey and information on the Advisory Board are available at the following URL:

Phoenix Healthcare, a part of Phoenix Marketing International, is one of the fastest growing research companies in the U.S.

Contact Information